CelLBxHealth plc
CelLBxHealth plc, a medical diagnostic company, develops cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. The company develops Parsortix PC1 systems, a medical device for the capture and harvest of intact circulating tumour cells (CTCs) from metastatic breast cancer patient blood for subsequent user-validated downstream analysis; and Parsortix PR1 sys… Read more
CelLBxHealth plc (CLBX) - Net Assets
Latest net assets as of December 2024: GBX18.44 Million GBX
Based on the latest financial reports, CelLBxHealth plc (CLBX) has net assets worth GBX18.44 Million GBX as of December 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (GBX25.46 Million) and total liabilities (GBX7.02 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | GBX18.44 Million |
| % of Total Assets | 72.44% |
| Annual Growth Rate | -22.95% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 17.21 |
CelLBxHealth plc - Net Assets Trend (2021–2024)
This chart illustrates how CelLBxHealth plc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for CelLBxHealth plc (2021–2024)
The table below shows the annual net assets of CelLBxHealth plc from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | GBX18.44 Million | -19.61% |
| 2023-12-31 | GBX22.94 Million | -42.74% |
| 2022-12-31 | GBX40.06 Million | -0.66% |
| 2021-12-31 | GBX40.33 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to CelLBxHealth plc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4933700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | GBX151.59 Million | 822.01% |
| Total Equity | GBX18.44 Million | 100.00% |
CelLBxHealth plc Competitors by Market Cap
The table below lists competitors of CelLBxHealth plc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
COTI
PINK:COTI
|
$942.00 |
|
PANASIAN POWER PLC
CM:PAPN0000
|
$942.86 |
|
China Lending Corp
PINK:RAHGF
|
$943.01 |
|
Cel AI PLC
LSE:CLAI
|
$943.23 |
|
Mughal Energy Ltd
KAR:GEMMEL
|
$941.47 |
|
CNVISION MEDIA
BE:CBW
|
$939.99 |
|
Lanka Realty Investments PLC
CM:ASCON0000
|
$939.94 |
|
Core Nickel Corp.
V:CNCO
|
$939.29 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CelLBxHealth plc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 22,939,000 to 18,441,000, a change of -4,498,000 (-19.6%).
- Net loss of 14,225,000 reduced equity.
- New share issuances of 8,631,000 increased equity.
- Other factors increased equity by 1,096,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | GBX-14.22 Million | -77.14% |
| Share Issuances | GBX8.63 Million | +46.8% |
| Other Changes | GBX1.10 Million | +5.94% |
| Total Change | GBX- | -19.61% |
Book Value vs Market Value Analysis
This analysis compares CelLBxHealth plc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 16.62x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 5.55x to 16.62x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | GBX0.17 | GBX0.95 | x |
| 2022-12-31 | GBX0.15 | GBX0.95 | x |
| 2023-12-31 | GBX0.09 | GBX0.95 | x |
| 2024-12-31 | GBX0.06 | GBX0.95 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently CelLBxHealth plc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -77.14%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -497.03%
- • Asset Turnover: 0.11x
- • Equity Multiplier: 1.38x
- Recent ROE (-77.14%) is below the historical average (-64.06%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -37.22% | -1481.93% | 0.02x | 1.17x | GBX-19.05 Million |
| 2022 | -54.13% | -2083.19% | 0.02x | 1.24x | GBX-25.69 Million |
| 2023 | -87.76% | -920.95% | 0.07x | 1.36x | GBX-22.43 Million |
| 2024 | -77.14% | -497.03% | 0.11x | 1.38x | GBX-16.07 Million |
Industry Comparison
This section compares CelLBxHealth plc's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $7,337,575
- Average return on equity (ROE) among peers: 28.47%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CelLBxHealth plc (CLBX) | GBX18.44 Million | -37.22% | 0.38x | $941.82 |
| Abingdon Health Plc (ABDX) | $5.81 Million | 59.68% | 0.19x | $1.83K |
| genedrive plc (GDR) | $8.86 Million | -2.75% | 0.18x | $1.10K |